Famitinib

Legal status

• Investigational

CAS Number

• 1044040-56-3

PubChem CID

• 16662431

IUPHAR/BPS

• 7886

Famitinib

Legal status
Legal status	Investigational
Identifiers
IUPAC name 5-[2-(Diethylamino)ethyl]-2-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-3-methyl-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4-one
CAS Number	1044040-56-3
PubChem CID	16662431
IUPHAR/BPS	7886
DrugBank	DB11741
ChemSpider	17595500
UNII	768FW21J3L
ChEMBL	ChEMBL1278146
CompTox Dashboard (EPA)	DTXSID301358976
Chemical and physical data
Formula	C23H27FN4O2
Molar mass	410.493 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCN(CC)CCN1CCC2=C(C1=O)C(=C(N2)/C=C\3/C4=C(C=CC(=C4)F)NC3=O)C
InChI InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13- Key:GKEYKDOLBLYGRB-LGMDPLHJSA-N

Famitinib is a tyrosine kinase receptor inhibitor developed by Jiangsu Hengrui for a variety of cancers.^{[1][2][3][4][5][6]} In China, in May 2025 famitinib was conditionally approved for use in combination with camrelizumab for the treatment of recurrent or metastatic cervical cancer in patients who have failed prior platinum-based chemotherapy and have not received prior bevacizumab.^[7]